Key Takeaways
- The Supreme Court has questioned the Centre's decision to cap trade margins at 30% for non-scheduled cancer drugs
- The proposed trade-margin rationalisation is expected to reduce the MRP of anti-cancer drugs by 20% to 70%
- The Centre has been given until October 27 to work out the modalities for capping medicine prices
Introduction
The Supreme Court has questioned the Centre's decision to cap trade margins at 30% for non-scheduled cancer drugs, asking why the benefit of such price regulation should not be extended to other essential medicines and medical products.
This development comes after a Bench of Justices Vikram Nath and Sandeep Mehta expressed concern over stark disparities between the price to retailer and the maximum retail price of certain medicines, particularly cancer drugs.
Background
The Centre informed the Supreme Court that it had decided to cap trade margins at 30% for non-scheduled cancer drugs, with an expert committee tasked with identifying the drugs to be brought within its ambit.
The National Pharmaceutical Pricing Authority (NPPA) will examine the committee's recommendations before issuing a price notification to implement the cap.
Concerns Over Price Disparities
Justice Mehta drew attention to steep markups on medical devices and consumables, pointing out that an India-made cardiac stent costing around โน5,000 was being sold by hospitals for more than โน25,000.
The Bench also cited the example of a saline drip line carrying an MRP of โน11 being sold for โน270.
Centre's Response
Additional Solicitor General Aishwarya Bhati cautioned against a uniform cap across medicines, arguing that low-value products often required higher margins to remain commercially viable for retailers.
Excessive regulation, she said, could discourage retailers from stocking such medicines and affect their availability, particularly in rural areas.
Bench's Observations
The Bench, however, was not persuaded, observing that ensuring the availability of price-controlled medicines was the government's responsibility.
Justice Mehta said that if the DPCO-approved medicines do not reach customers, then it is the duty of the government to ensure it reaches the patient.
Way Forward
The Centre has been given until October 27 to work out the modalities for capping medicine prices, when the matter will be heard next.
Read also: Cancer Treatment Costs Reduced
The Centre said the proposed trade-margin rationalisation was expected to reduce the MRP of anti-cancer drugs by 20% to 70%, translating into estimated annual savings of around โน2,500 crore.
Existing Price-Control Mechanism
The Centre said the ceiling price of medicines listed in Schedule I of the DPCO is determined by taking the simple average of the price to retailer of brands and generic versions with a market share of at least 1%, and adding a 16% margin.
- The ceiling price so fixed becomes the MRP, i.e., the price above which the drug cannot be sold in the market.
- However, the manufacturer is at liberty to give an appropriate margin to the wholesaler and the retailer within the ceiling price.
Ceiling prices have so far been fixed for 935 formulations.
Implications for India
The Supreme Court's intervention is expected to have a significant impact on the pharmaceutical industry in India, with the potential to reduce prices and improve affordability for patients.
The move could also lead to increased access to essential medicines, particularly in rural areas where availability is often a concern.
Expert Perspective
Experts in the pharmaceutical industry have welcomed the Supreme Court's move, saying it could help reduce the financial burden on patients and improve healthcare outcomes.
However, some have also cautioned that excessive regulation could have unintended consequences, such as affecting the availability of certain medicines or discouraging innovation.
Timeline
The Centre has been given until October 27 to work out the modalities for capping medicine prices, when the matter will be heard next.
The Supreme Court's decision is expected to have a significant impact on the pharmaceutical industry in India, and the outcome of the case will be closely watched by stakeholders.
Conclusion
The Supreme Court's intervention in the matter of price regulation for essential medicines is a significant development, with the potential to improve affordability and access to healthcare for patients in India.
Key figures include a proposed 30% trade-margin cap, estimated annual savings of around โน2,500 crore, and a 20% to 70% reduction in the MRP of anti-cancer drugs.
Frequently Asked Questions
What is the proposed trade-margin cap for non-scheduled cancer drugs?
The proposed trade-margin cap is 30%
What is the expected reduction in the MRP of anti-cancer drugs?
The expected reduction is 20% to 70%
What is the deadline for the Centre to work out the modalities for capping medicine prices?
The deadline is October 27
